ISRCTN17468602终止未知
SEL-I-METRY: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy
Sheffield Teaching Hospitals NHS Trust0 个研究点目标入组 30 人开始时间: 2015年12月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 终止
- 发起方
- 入组人数
- 30
研究概览
简要总结
2019 Protocol article in https://pubmed.ncbi.nlm.nih.gov/31200667/ protocol (added 08/12/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current participant inclusion criteria as of 03/11/2021:
- •1. Diagnosed with locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hürthle cell, or poorly differentiated carcinoma) with at least one measurable lesion as measured by computed tomography (CT) or magnetic resonance imaging (MRI)
- •2. Participants must have iodine refractory disease, defined below:
- •2.1. One or more measurable lesions that do not demonstrate iodine uptake on a previous radioiodine scan (diagnostic uptake or post therapy)
- •2.2. One or more measurable lesions that have progressed by RECIST 1.1 criteria within 12 months of I131 therapy, despite demonstrable radioiodine avidity at the time of that treatment
- •3. Participants must have radiological progression by RECIST 1.1 criteria within the prior 12 months
- •4. Measurable disease by RECIST 1.1 criteria. Baseline scan must be completed within 4 weeks prior to the start of treatment.
- •5. ECOG Performance Status = 1 and able to tolerate radioiodine therapy
- •6. Life expectancy of at least 12 weeks
- •7. Required laboratory values within 14 days of day 1 of treatment:
- •7.1. Adequate thyroidstimulating hormone (TSH) suppression < 0.5 mU/L
- •7.2. Creatinine clearance >50 ml/min,
- •7.3. Absolute Neutrophil Count =1.5x109/L (1500 per mm3)
- •7.4. Platelets =100x109/L (100,000 per mm3)
- •7.5. Haemoglobin >9.0 g/dL
- •7.6. Serum bilirubin =1.5 x upper limit of normal (ULN)
- •7.7. Patients with no liver metastasis must have AST or ALT = 2.5 x ULN
- •7.8. Patients with liver metastasis must have AST or ALT = 5 x ULN. If patients have AST or ALT > 3.5 x ULN and = 5 x ULN they must have an ALP= 6 x ULN
- •8. Patient’s with Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the
- •absence of evidence of haemolysis or hepatic pathology) will be eligible.
- •9. Able to give informed consent and willing to follow trial protocol.
- •10. Aged over 18
- •11. Female participants of childbearing potential must have a negative pregnancy test within 24 hours prior to starting therapy and agree to use dual methods of contraception for the duration of the trial and 6 months after completing treatment. Male participants must agree to use a barrier method of contraception for the duration of the trial and 4 months after completing treatment, if sexually active with a female of childbearing
- •Previous participant inclusion criteria:
- •1. Diagnosed with locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hürthle cell, or poorly differentiated carcinoma) with at least one measurable lesion as measured by computed tomography (CT) or magnetic resonance imaging (MRI)
- •2. Participants must have iodine refractory disease, defined below:
- •2.1. One or more measurable lesions that do not demonstrate iodine uptake on a previous radioiodine scan (diagnostic uptake or post therapy)
- •2.2. One or more measurable lesions that have progressed by RECIST 1.1 criteria within 12 months of I131 t
排除标准
- •Current participant exclusion criteria as of 03/11/2021:
- •1. Foci of anaplastic thyroid cancer identified on histology
- •2. Able to receive curative surgery or radiation therapy
- •3. Major surgery with the exception of surgical placement for vascular access, open biopsy, or significant traumatic injury = 30 days prior to registration
- •4. Previous or concurrent cancer distinct in primary site or histology from thyroid cancer within previous 5 years, except for cervical cancer in situ, treated basal cell carcinoma, squamous cell carcinoma of the skin or superficial bladder tumour
- •5. Have received or are receiving an IMP or other systemic anticancer treatment within 4 weeks prior to the first dose of study treatment (6 weeks for nitrosoureas, mitomycin, and suramin), or within a period during which the IMP or anticancer treatment has not been cleared from the body (e.g. a period of 5 ‘halflives’), whichever is the most appropriate and as judged by the investigator
- •6. Any unresolved toxicity =CTCAE Grade 2 from previous anticancer therapy, except for alopecia
- •7. Prior exposure to Tyrosine Kinase, MEK, RAS or RAF inhibitors
- •8. Known or suspected allergy to Selumentinib or hypersensitivity to Selumetinib or any excipient agents or history of allergic reactions attributed to compounds of similar chemical or biologic composition to Selumetinib
- •9. Known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic, has been treated with surgery and / or radiation, and has been stable without requiring corticosteroids nor anticonvulsant medications for at least 4 weeks prior to the first dose of study medication
- •10. Requiring medication with high iodine content (e.g. amiodarone)
- •11. Participants who have had a iodine contrast enhanced CT scan in previous 2 months
- •12. Ophthalmological conditions as follows:
- •12.1 Intra-ocular pressure >21 mmHg, or uncontrolled glaucoma (irrespective of intra-ocular pressure)
- •12.2 Current or past history of retinal pigment epithelial detachment (REPD)/central serous retinopathy or retinal vein occlusion
- •13. Any of the following cardiac conditions:
- •13.1 Uncontrolled hypertension (BP >150/95 mmHg despite medical therapy)
- •13.2 Acute coronary syndrome within 6 months prior to starting treatment
- •13.3 Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical therapy)
- •13.4 Symptomatic heart failure (NYHA grade II-IV), prior or current cardiomyopathy, or severe vascular disease
- •13.5 Prior or current cardiomyopathy including but not limited to the following:
- •13.5.1 known hypertrophic cardiomyopathy
- •13.5.2 known arrhythmogenic right ventricular cardiomyopathy
- •13.6 Severe valvular heart disease
- •13.7 Left ventricular ejection fraction <55% measured by echocardiography
- •13.8 Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest
- •13.9 QTcF >450ms or other factors that increase the risk of QT prolongation
- •14. Participants known to be infected with human immunodeficiency virus (HIV) or hepatitis B
研究者
相似试验
已完成
不适用
A research study in Uganda to test an intervention called DIALOG+, designed to improve care for people living in the community with severe mental illnessMental, neurological and substance misuse disorders, which includes severe mental illness (psychosis, severe depression and anxiety), epilepsy and comorbid substance misuseMental and Behavioural DisordersISRCTN25146122Queen Mary University of London182
已完成
不适用
People regulating themselves to achieve weight loss (Prevail Trial)Nutritional, Metabolic, EndocrineObesityISRCTN14148239niversity of Oxford / Clinical Trials and Research Governance (CTRG)100
已完成
4 期
A study of pre-clinical joint disease in psoriasis and the imaging response to ustekinumabPsoriatic disease (psoriasis and psoriatic arthritis)Skin and Connective Tissue DiseasesPsoriasisISRCTN18043449niversity of Leeds (UK)73
进行中（未招募）
不适用
The evaluation of the insertion parameters and complications of the i-gel Plus airway device for maintaining patent airway during planned procedures under general anaesthesiaAirway management in patients under general anaesthesiaSurgeryISRCTN86233693Vseobecna fakultni nemocnice (General University Hospital)2,000
已完成
不适用
A research intervention in Uganda to test an intervention called Volunteer Support, designed to improve care for people living in the community with severe mental illnessPatients with severe mental illness (including psychosis)Mental and Behavioural DisordersISRCTN86689958Queen Mary University of London70